Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
Massachusetts General Hospital
M.D. Anderson Cancer Center
Seattle Children's Hospital
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Columbia University